Lanean...
Istradefylline reduces memory deficits in aging mice with amyloid pathology
Adenosine A(2A) receptors are putative therapeutic targets for neurological disorders. The adenosine A(2A) receptor antagonist istradefylline is approved in Japan for Parkinson’s disease and is being tested in clinical trials for this condition elsewhere. A(2A) receptors on neurons and astrocytes ma...
Gorde:
| Argitaratua izan da: | Neurobiol Dis |
|---|---|
| Egile Nagusiak: | , , , , , , , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5747997/ https://ncbi.nlm.nih.gov/pubmed/29100987 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nbd.2017.10.014 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|